Skip to search formSkip to main contentSkip to account menu

PI3K-beta Inhibitor GSK2636771

Known as: GSK2636771 
An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Purpose: OX40 agonist–based combinations are emerging as a novel avenue to improve the effectiveness of cancer immunotherapy. To… 
2018
2018
Phosphatidylinositol 3‐kinase β and β isoforms play key roles in metastasis of prostate cancer DU145 cells
Metastasis is the main cause of the lethality of prostate cancer. Class I phosphatidylinositol 3‐kinases (PI3Ks), which contain 4… 
2018
2018
Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
TPS9596Background: Immune checkpoint blockade (ICB) improves overall survival and provides long-term disease control in 35-40% of… 
Highly Cited
2017
Highly Cited
2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110… 
2017
2017
Characterization of a novel p110β‐specific inhibitor BL140 that overcomes MDV3100‐resistance in castration‐resistant prostate cancer cells
Our previous studies demonstrated that the class IA PI3K/p110β is critical in castration‐resistant progression of prostate cancer… 
2016
2016
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
Purpose: Determine the roles of the PI3K isoforms p110α and p110β in PTEN-deficient, estrogen receptor α (ER)-positive breast… 
2016
2016
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
BackgroundThe phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising… 
2015
2015
Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors
Background: GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ (apparent Ki = 0.89 nM), with >900-fold… 
2014
2014
A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.
2514^ Background: GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ (0.89 nM), with >900-fold… 
2012
2012
Abstract 2913: Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kα) for the treatment of PTEN deficient tumors
Dysregulation of the PI3K pathway is one of the most common causes of tumorigenesis. Aberrant pathway activation occurs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)